NCT05356507 is a clinical trial of Patient population in Brain Tumor, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05356507?

NCT05356507 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05356507?

Interventions in NCT05356507: Patient population.

What condition does NCT05356507 study?

NCT05356507 studies Brain Tumor.

Is NCT05356507 still recruiting?

NCT05356507 is currently withdrawn. Last updated 2 February 2023.

Last reviewed 2023-02-02 · How we verify

NCT05356507

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Spiritual Needs on Spiritual Well-Being in Patients With Brain Tumors: A Structural Equation Modeling Approach

Withdrawn Last updated 2 February 2023

What this trial tests

trial testing Patient population in Brain Tumor. Withdrawn.

Timeline

29 August 2022

Primary endpoint
31 January 2023

31 January 2023

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	29 August 2022
Primary completion	31 January 2023
Estimated completion	31 January 2023
Sites	1 location across United States

Drugs / interventions tested

Patient population

Conditions studied

Brain Tumor — all drugs for Brain Tumor →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to describe a patient's Spiritual Needs and related factors that contribute to a patient's Spiritual Well-Being in the context of perioperative care. The primary objective of this study is to examine the fit of the Structural Equation Model (SEM) of the theory on Spiritual Well-Being (SWB) and explain how SWB is affected by Symptom Burden (SB), Psychological Distress (PsD), and Spiritual Needs (SN) reported by the patients with brain tumors before having surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Patient population

Trials testing the same drug.

NCT05305950 — Barriers and Facilitators in Access to OT/PT in Pediatric Cancer Survivors · active not recruiting

Other recruiting trials for Brain Tumor

Currently open trials in the same condition.

NCT07224503 — C-SMART vs BE Well for Patients With Brain Tumors · NA · recruiting
NCT07323966 — Feasibility of Mask-Free Radiotherapy for Brain Tumor Patients · NA · recruiting
NCT07122752 — Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy · active not recruiting
NCT07105358 — Visual Plasticity Following Brain Lesions · NA · recruiting
NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05356507 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 2 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05356507.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing